Increasing Prevalence Of Fungal Infections Fueling The Growth Of The Market Due To Rising Immunocompromised Population And Poor Hygiene: A Significant Driver Propelling The Dermatomycoses Market In 2025

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Dermatomycoses Market Size and Projected Growth Rate?
The market size of dermatomycoses has seen robust growth in the past few years. Its growth is forecasted to increase from $14.12 billion in 2024 to $14.95 billion in 2025, representing a compound annual growth rate (CAGR) of 5.9%. Factors contributing to this historical period growth include strides in antifungal treatment development, higher prevalence of fungal infections, escalating skin health consciousness, the introduction of better diagnostic techniques, and the expansion of over-the-counter antifungal product offerings.

In the coming years, the dermatomycoses market is anticipated to witness robust expansion. It is projected to reach $18.59 billion by 2029, growing at a compound annual growth rate (CAGR) of 5.6%. Factors contributing to the forecasted growth include the rising elderly population, an upsurge in drug-resistant fungal strains, increasing demand for natural and organic antifungal products, advancements in biotechnology and antifungal research, and a broader healthcare access in developing regions. The forecast period is also expected to observe key trends such as the invention of new antifungal medications, progressive developments in quick diagnostic procedures, the application of artificial intelligence in dermatology, advancements in nanotechnology-based antifungal treatments, and progress in microbiome-linked therapies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21934

What Are the Major Segments in the Dermatomycoses Market?
The dermatomycoses market covered in this report is segmented -

1) By Drugs: Corticosteroids, Corticosteroid-Sparing Agents, Immunosuppressive, Immunomodulator, Antifungals, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Topical, Other Routes Of Administration
3) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegmentss:

1) By Corticosteroids: Topical Corticosteroids, Oral Corticosteroids, Injectable Corticosteroids
2) By Corticosteroid-Sparing Agents: Tacrolimus, Pimecrolimus
3) By Immunosuppressive: Methotrexate, Azathioprine, Cyclophosphamide
4) By Immunomodulator: Interferon-Gamma, Thalidomide
5) By Antifungals: Topical Antifungals, Oral Antifungals, Systemic Antifungals
6) By Other Drugs: Antihistamines, Antibacterial Agents

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21934&type=smp

What Are The Driving Dermatomycoses Market Evolution?
Growth in the dermatomycoses market is being spurred on by the escalating occurrence of fungal infections. These infections, caused by fungi, can affect a variety of body parts, including the skin, nails, hair, and internal organs, leading to a number of health complications. Over-reliance on broad-spectrum antibiotics disrupts the natural microbiome balance, rendering it a suitable environment for fungi to proliferate and thus cause infections. Moreover, this imbalance compromises the body's natural defenses, rendering it more susceptible to opportunistic fungal infections. A variety of fungal diseases, including dermatomycoses, can arise from dermatophytes, yeasts, and molds, affecting different tissues and resulting in common superficial and systemic infections. The UK Health Security Agency revealed in November 2023 that an estimated 6.5 million invasive fungal infections occur annually, leading to roughly 3.8 million deaths, 2.5 million of which can be directly linked to these infections. Hence, the growing number of fungal infections is fueling the dermatomycoses market. A surge in the demand for oral drugs because of their comfort and effectiveness is also contributing to the dermatomycoses market's growth. Oral drugs, consumed orally in forms such as tablets, capsules, or liquids, are absorbed via the digestive tract. These drugs are popular due to their convenience and efficacy in treating a broad array of disorders, which gives them an edge over injections or other methods of administration. Oral drugs are supported by dermatomycoses as systemic antifungal agents can infiltrate the infected skin, nails, or hair through the bloodstream, offering more extensive and prolonged treatment than topical applications. The Centers for Disease Control and Prevention in the United States reported a 57% rise in the dispensing of oral antivirals between April 24 and August 28, 2022, soaring from 643 per 100,000 people to 1,012 per 100,000 people. The escalating demand for oral drugs is therefore propelling the dermatomycoses market forward.

Which Firms Dominate The Dermatomycoses Market Segments?
Major companies operating in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz

What Trends Are Expected to Dominate the Dermatomycoses Market in the Next 5 Years?
Key players in the dermatomycoses market are concentrating their efforts on developing new drugs to enhance the treatment of onychomycosis and optimize its efficacy. These pharmaceutical compounds, known as investigational new drugs (INDs), are undergoing preclinical or clinical evaluations to confirm their safety and effectiveness in preparation for potential regulatory approval and subsequent clinical use. As an example, in January 2024, the US-based biopharmaceutical entity, Vanda Pharmaceuticals Inc., had their Investigational New Drug, VTR-297, greenlit for onychomycosis treatment by the US Food and Drug Administration (FDA). The drug sets itself apart from other treatments due to its unique histone deacetylase (HDAC) inhibitory functions, which differentiate it from traditional antifungal therapies. The drug targets the origin of fungal growth, proving powerfully effective against dermatophyte fungi and others. This pioneering therapeutic approach could possibly result in swifter, more effective treatment outcomes, while minimizing the possibility of reinfection, thus addressing a crucial gap in onychomycosis therapy.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/dermatomycoses-global-market-report

Which Is The Largest Region In The Dermatomycoses Market?
North America was the largest region in the dermatomycoses market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dermatomycoses market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Dermatomycoses Market?
2. What is the CAGR expected in the Dermatomycoses Market?
3. What Are the Key Innovations Transforming the Dermatomycoses Industry?
4. Which Region Is Leading the Dermatomycoses Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.